About all

Pravastatin sodium 20 mg side effects. Pravastatin Sodium 20mg: Understanding Side Effects, Dosage, and Interactions

by alexxlab

What are the common side effects of Pravastatin Sodium 20mg. How does Pravastatin interact with other medications. What precautions should be taken when using Pravastatin. When should you consult a healthcare professional while taking Pravastatin.

Содержание

Understanding Pravastatin Sodium: A Comprehensive Overview

Pravastatin Sodium is a widely prescribed medication belonging to the class of drugs known as statins. It’s primarily used to lower cholesterol levels and reduce the risk of cardiovascular diseases. The 20mg dosage is a common prescription strength, balancing efficacy and tolerability for many patients.

Pravastatin works by inhibiting an enzyme called HMG-CoA reductase, which plays a crucial role in cholesterol production in the liver. By doing so, it helps to lower LDL (bad) cholesterol and triglycerides while slightly increasing HDL (good) cholesterol levels.

Key Features of Pravastatin Sodium 20mg

  • Active ingredient: Pravastatin Sodium
  • Dosage strength: 20mg
  • Drug class: HMG-CoA reductase inhibitors (statins)
  • Primary use: Lowering cholesterol and reducing cardiovascular risk
  • Administration: Oral tablet, typically taken once daily

Common Side Effects of Pravastatin Sodium 20mg

While Pravastatin is generally well-tolerated, like all medications, it can cause side effects in some individuals. Understanding these potential side effects is crucial for patients and healthcare providers alike.

Are common side effects of Pravastatin Sodium 20mg typically mild. Yes, most patients experience either no side effects or only mild ones that often subside as the body adjusts to the medication. However, it’s important to be aware of these potential effects:

  • Headache
  • Nausea
  • Diarrhea
  • Muscle pain or weakness
  • Fatigue
  • Dizziness
  • Abdominal pain
  • Constipation

These side effects are usually transient and mild. However, if they persist or worsen, it’s advisable to consult a healthcare professional.

Rare but Serious Side Effects to Watch For

While rare, some side effects of Pravastatin Sodium 20mg can be serious and require immediate medical attention. Recognizing these potential effects is crucial for patient safety.

Can Pravastatin cause severe muscle problems. In rare cases, yes. Statins, including Pravastatin, have been associated with a condition called rhabdomyolysis, which involves the breakdown of muscle tissue. This can lead to kidney damage if left untreated.

Signs of Serious Side Effects

  1. Unexplained muscle pain, tenderness, or weakness
  2. Dark or cola-colored urine
  3. Fever
  4. Unusual tiredness
  5. Yellowing of the skin or eyes (jaundice)
  6. Signs of an allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing)

If any of these symptoms occur, it’s crucial to seek immediate medical attention. While these side effects are rare, they can be serious if not addressed promptly.

Pravastatin Dosage and Administration

The correct dosage of Pravastatin Sodium is crucial for its effectiveness and safety. While 20mg is a common dosage, the optimal amount can vary based on individual factors.

How should Pravastatin Sodium 20mg be taken. Pravastatin is typically taken orally once daily, with or without food. It’s often recommended to take it in the evening, as cholesterol production in the body tends to be highest at night.

Dosage Considerations

  • Starting dose: Often 20mg or 40mg once daily
  • Maximum dose: 80mg once daily
  • Adjustments: May be necessary based on response and tolerability
  • Special populations: Lower doses may be recommended for elderly patients or those with kidney or liver impairment

It’s crucial to follow the prescribed dosage and not to adjust it without consulting a healthcare provider. Missing doses or stopping the medication abruptly can affect its effectiveness and potentially lead to health risks.

Drug Interactions with Pravastatin Sodium

Understanding potential drug interactions is crucial for patients taking Pravastatin Sodium 20mg. These interactions can affect the medication’s efficacy or increase the risk of side effects.

Does Pravastatin interact with many other medications. Yes, Pravastatin can interact with several types of drugs, including other cholesterol-lowering medications, certain antibiotics, and drugs used to treat various conditions.

Notable Drug Interactions

  1. Fibrates (e.g., gemfibrozil): Can increase the risk of muscle problems
  2. Cyclosporine: May increase Pravastatin levels in the blood
  3. Clarithromycin and other macrolide antibiotics: Can increase Pravastatin levels
  4. Warfarin: Pravastatin may enhance the anticoagulant effect
  5. Cholestyramine: Can decrease Pravastatin absorption if taken together
  6. Certain HIV medications: May affect Pravastatin metabolism

It’s essential to inform healthcare providers about all medications, including over-the-counter drugs and supplements, to avoid potential interactions.

Precautions and Warnings for Pravastatin Use

While Pravastatin Sodium 20mg is generally safe and effective, certain precautions should be observed to ensure its safe use and maximize its benefits.

Are there specific groups who should use Pravastatin with caution. Yes, certain populations need to be particularly careful when using Pravastatin:

  • Pregnant women or those planning pregnancy
  • Breastfeeding mothers
  • Individuals with liver disease
  • People with kidney problems
  • Those with a history of muscle disorders
  • Individuals consuming large amounts of alcohol

These groups may require closer monitoring, dosage adjustments, or alternative treatments. It’s crucial to discuss any pre-existing conditions or lifestyle factors with a healthcare provider before starting Pravastatin.

Lifestyle Considerations

To maximize the benefits of Pravastatin and minimize risks:

  • Maintain a healthy diet low in saturated fats and cholesterol
  • Engage in regular physical activity
  • Limit alcohol consumption
  • Quit smoking if applicable
  • Monitor liver function regularly as advised by your doctor

Long-Term Effects and Monitoring

Understanding the long-term effects of Pravastatin Sodium 20mg is crucial for patients who may be on this medication for extended periods.

Is long-term use of Pravastatin safe. Generally, yes. Pravastatin has been used safely for many years, and long-term studies have shown its efficacy in reducing cardiovascular risks. However, ongoing monitoring is essential.

Long-Term Monitoring Requirements

  1. Regular lipid profile tests to assess cholesterol levels
  2. Liver function tests, especially in the first year of treatment
  3. Monitoring for muscle-related symptoms
  4. Blood glucose levels, as statins may slightly increase the risk of diabetes
  5. Regular check-ups to assess overall cardiovascular health

Long-term use of Pravastatin requires a partnership between the patient and healthcare provider to ensure ongoing safety and efficacy. Regular check-ups and open communication about any new symptoms or concerns are crucial.

Alternatives and Complementary Treatments

While Pravastatin Sodium 20mg is an effective medication for many, it’s not the only option for managing cholesterol levels and cardiovascular risk. Understanding alternatives and complementary treatments can provide a more comprehensive approach to heart health.

Are there non-statin alternatives to Pravastatin. Yes, several other medication classes and lifestyle interventions can be used either as alternatives or in conjunction with statins:

Alternative Medications

  • Bile acid sequestrants (e.g., cholestyramine)
  • Fibrates (e.g., fenofibrate)
  • Niacin (vitamin B3)
  • Ezetimibe
  • PCSK9 inhibitors (for severe cases)

Lifestyle Interventions

  1. Mediterranean diet or other heart-healthy eating plans
  2. Regular aerobic exercise and strength training
  3. Weight management
  4. Stress reduction techniques like meditation or yoga
  5. Omega-3 fatty acid supplementation

These alternatives may be used alone or in combination with Pravastatin, depending on individual needs and response to treatment. It’s essential to discuss these options with a healthcare provider to determine the most appropriate approach.

Patient Experiences and Quality of Life

Understanding how Pravastatin Sodium 20mg affects patients’ daily lives and overall well-being is crucial for both healthcare providers and potential users of the medication.

How does Pravastatin impact patients’ quality of life. For many, Pravastatin significantly improves quality of life by reducing the risk of cardiovascular events and providing peace of mind. However, experiences can vary:

Positive Impacts

  • Reduced anxiety about cardiovascular health
  • Improved lipid profiles leading to better overall health
  • Minimal side effects for most users
  • Convenience of once-daily dosing

Potential Challenges

  1. Muscle aches or weakness in some users
  2. Need for regular medical check-ups and blood tests
  3. Potential interactions with other medications or dietary supplements
  4. Concerns about long-term use of medication

Patient experiences with Pravastatin can vary widely. While many report significant benefits with minimal side effects, others may face challenges. Open communication with healthcare providers is key to addressing concerns and optimizing treatment.

Future Developments and Research

The field of cardiovascular medicine is constantly evolving, and research into statins like Pravastatin Sodium continues to advance our understanding of their benefits and potential new applications.

What new developments are occurring in statin research. Several exciting areas of research are expanding our knowledge of statins:

Emerging Research Areas

  • Potential neuroprotective effects in conditions like Alzheimer’s disease
  • Role in reducing inflammation and potential applications in autoimmune disorders
  • Personalized medicine approaches to optimize statin therapy
  • Combination therapies with newer cholesterol-lowering drugs
  • Long-term effects on overall mortality and quality of life

These research directions may lead to expanded uses for Pravastatin and other statins, as well as improved strategies for their use in cardiovascular prevention and treatment.

Technological Advancements

  1. Development of new drug delivery systems for improved efficacy
  2. Genetic testing to predict individual responses to statin therapy
  3. Advanced imaging techniques to better assess cardiovascular risk and statin effects
  4. AI-driven algorithms for optimizing statin dosing and predicting outcomes

As research progresses, our understanding of Pravastatin and its optimal use continues to evolve, potentially leading to more personalized and effective treatment strategies for cardiovascular health.

Side Effects of Pravachol (Pravastatin Sodium), Warnings, Uses

000035178_PB

square, yellow, imprinted with PRAVACHOL 20, LOGO P

000035194_PB

square, green, imprinted with PRAVACHOL 40, LOGO P

000035195_PB

oval, yellow, imprinted with BMS, 80

000930771_PB

round, pink, imprinted with 771, TEVA

000937201_PB

round, yellow, imprinted with TEVA, 7201

000937270_PB

oval, white, imprinted with 7270, TEVA

007815231_PB

round, brown, imprinted with HLP 10

007815234_PB

round, brown, imprinted with HLP 40

007815235_PB

oval, brown

009045891_PB

round, pink, imprinted with APO, PRA 10

009045892_PB

round, yellow, imprinted with APO, PRA 20

009045893_PB

round, green, imprinted with APO, PRA 40

422910665_PB

round, pink, imprinted with TEVA, 771

422910667_PB

round, yellow, imprinted with TEVA, 7201

422910668_PB

round, green, imprinted with TEVA, 7202

422910669_PB

oval, gray, imprinted with TEVA, 7270

510790458_PB

round, yellow, imprinted with TEVA, 7201

604290367_PB

round, pink, imprinted with APO, PRA 10

604290368_PB

round, yellow, imprinted with APO, PRA 20

604290369_PB

round, green, imprinted with APO, PRA 40

605050168_PB

round, pink, imprinted with APO, PRA 10

605050169_PB

round, yellow, imprinted with APO, PRA 20

605050170_PB

round, green, imprinted with APO, PRA 40

605051323_PB

round, yellow, imprinted with APO, PRA 80

684620195_PB

round, yellow, imprinted with G5, 10

684620196_PB

rectangular, yellow, imprinted with G5, 20

684620197_PB

rectangular, green, imprinted with G5, 40

684620198_PB

oval, yellow, imprinted with G5, 80

Pravachol 10 mg

square, pink, imprinted with PRAVACHOL 10, LOGO P

Pravachol 20 mg

square, yellow, imprinted with PRAVACHOL 20, LOGO P

Pravachol 40 mg

square, green, imprinted with PRAVACHOL 40, LOGO P

Pravachol 80 mg

oval, yellow, imprinted with BMS, 80

Pravastatin 10 mg-TEV

round, pink, imprinted with 93, 771

pravastatin 10mg 502680665

round, pink, imprinted with APO, PRA 10

Pravastatin 20 mg-MYL

square, white, imprinted with PR 20, G

pravastatin 20mg 502680666

round, yellow, imprinted with APO, PRA 20

Pravastatin 40 mg-MYL

square, white, imprinted with PR 40, G

Pravastatin 40 mg-TEV

round, green, imprinted with 93, 7202

Pravastatin 40 mg-TEV

round, green, imprinted with TEVA, 7202

pravastatin 40mg 502680667

round, green, imprinted with APO, PRA 40

Pravastatin 80 mg-COB

oval, white, imprinted with LOGO, PV 80

Pravastatin 80 mg-MYL

oval, white, imprinted with PR80, G

pravastatin 80mg 502680668

round, yellow, imprinted with APO, PRA 80

Pravachol (pravastatin) dosing, indications, interactions, adverse effects, and more

  • apalutamide

    Monitor Closely (1)apalutamide will decrease the level or effect of pravastatin by increasing elimination. Use Caution/Monitor. Apalutamide weakly induces OATP1B1 and may decrease systemic exposure of drugs that are OATP1B1 substrates.

  • avapritinib

    Monitor Closely (1)pravastatin will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

  • axitinib

    Monitor Closely (1)pravastatin increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

  • bempedoic acid

    Monitor Closely (1)bempedoic acid increases levels of pravastatin by unknown mechanism. Modify Therapy/Monitor Closely. Avoid concomitant use with pravastatin dose 40 mg.

  • berotralstat

    Monitor Closely (1)berotralstat will increase the level or effect of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor or titrate P-gp substrate dose if coadministered.

  • bosutinib

    Monitor Closely (1)bosutinib increases levels of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

  • carbamazepine

    Monitor Closely (1)carbamazepine increases toxicity of pravastatin by Other (see comment). Modify Therapy/Monitor Closely.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • caspofungin

    Monitor Closely (1)caspofungin increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • cholestyramine

    Monitor Closely (1)cholestyramine decreases levels of pravastatin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

  • clarithromycin

    Monitor Closely (2)clarithromycin increases levels of pravastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for myopathy; do not exceed pravastatin dose of 40 mg/day when coadministered with clarithromycin .

    clarithromycin increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • clotrimazole

    Monitor Closely (1)clotrimazole increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • cobicistat

    Monitor Closely (1)cobicistat will increase the level or effect of pravastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. For HMG-CoA reductase inhibitors that are not contraindicated with cobicistat, start with the lowest recommended dose and titrate while monitoring for safety.

  • coenzyme Q10

    Minor (1)pravastatin decreases levels of coenzyme Q10 by unspecified interaction mechanism. Minor/Significance Unknown.

  • colchicine

    Serious – Use Alternative (1)colchicine, pravastatin.
    Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of rhabdomyolysis (incl a fatality).

  • colestipol

    Minor (1)colestipol decreases levels of pravastatin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

  • crizotinib

    Monitor Closely (1)crizotinib increases levels of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

  • cyclosporine

    Serious – Use Alternative (1)cyclosporine increases toxicity of pravastatin by Other (see comment). Avoid or Use Alternate Drug.
    Comment: Cyclosporine, an OATP1B1 inhibitor, with pravastatin, OATP1B1 substrate, may increase risk of myopathy. Initiate pravastatin dose at 10 mg/day and not to exceed 20 mg/day in patients who are also receiving cyclosporine.

  • daptomycin

    Monitor Closely (1)pravastatin, daptomycin.
    Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely.
    Comment: Coadministration of daptomycin with HMG-CoA reductase inhibitors may increase CPK levels and risk for myopathy; consider temporary suspension of HMG-CoA reductase inhibitors during daptomycin therapy.

  • darunavir

    Monitor Closely (2)darunavir increases levels of pravastatin by unknown mechanism. Use Caution/Monitor.

    darunavir will increase the level or effect of pravastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. For HMG-CoA reductase inhibitors that are not contraindicated with darunavir, start with the lowest recommended dose and titrate while monitoring for safety.

  • elagolix

    Monitor Closely (1)elagolix will increase the level or effect of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

  • eliglustat

    Monitor Closely (1)eliglustat increases effects of pravastatin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.

  • eltrombopag

    Serious – Use Alternative (1)eltrombopag increases toxicity of pravastatin by Other (see comment). Avoid or Use Alternate Drug.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • eluxadoline

    Serious – Use Alternative (1)pravastatin increases levels of eluxadoline by decreasing metabolism. Avoid or Use Alternate Drug. Decrease eluxadoline dose to 75 mg PO BID if coadministered with OATP1B1 inhibitors. .

  • erythromycin base

    Monitor Closely (1)erythromycin base increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • erythromycin ethylsuccinate

    Monitor Closely (1)erythromycin ethylsuccinate increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • erythromycin lactobionate

    Monitor Closely (1)erythromycin lactobionate increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • erythromycin stearate

    Monitor Closely (1)erythromycin stearate increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • fenofibrate

    Serious – Use Alternative (1)fenofibrate, pravastatin.
    Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.

  • fenofibrate micronized

    Serious – Use Alternative (1)fenofibrate micronized, pravastatin.
    Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.

  • fenofibric acid

    Serious – Use Alternative (1)fenofibric acid, pravastatin.
    Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.

  • finerenone

    Monitor Closely (1)pravastatin will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.

  • flibanserin

    Monitor Closely (1)pravastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.

  • fostemsavir

    Monitor Closely (1)fostemsavir will increase the level or effect of pravastatin by Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits OATP1B1/3 transporter. If possible, avoid coadministration or modify dose of OATP1B1/3 substrates coadministered with fostemsavir. Use lowest possible starting dose for statins and monitor for associated adverse events.

  • gemfibrozil

    Contraindicated (1)gemfibrozil increases toxicity of pravastatin by Other (see comment). Contraindicated.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.Serious – Use Alternative (1)gemfibrozil, pravastatin.
    Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Gemfibrozil may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.

  • glecaprevir/pibrentasvir

    Monitor Closely (1)glecaprevir/pibrentasvir increases levels of pravastatin by Other (see comment). Modify Therapy/Monitor Closely.
    Comment: Increased statin concentrations resulting from OATP1B1 inhibition may increase risk of myopathy, including rhabdomyolysis. If coadministered, reduce pravastatin dose by 50%.

  • glyburide

    Monitor Closely (1)glyburide increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • indinavir

    Monitor Closely (1)indinavir increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • isradipine

    Minor (1)isradipine decreases levels of pravastatin by unknown mechanism. Minor/Significance Unknown.

  • istradefylline

    Monitor Closely (1)istradefylline will increase the level or effect of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of P-gp substrates in clinical trials. Consider dose reduction of sensitive P-gp substrates.

  • ivacaftor

    Monitor Closely (2)ivacaftor increases levels of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp; may significantly increase systemic exposure to sensitive P-gp substrates with a narrow therapeutic index.

    pravastatin increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .

  • ketoconazole

    Monitor Closely (1)ketoconazole increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • lanthanum carbonate

    Monitor Closely (1)lanthanum carbonate decreases levels of pravastatin by cation binding in GI tract. Use Caution/Monitor. Administer statin at least 2 hr before or 2 hr after lanthanum. Monitor serum concentrations.

  • lasmiditan

    Serious – Use Alternative (1)lasmiditan increases levels of pravastatin by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.

  • lemborexant

    Monitor Closely (1)pravastatin will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification.

  • letermovir

    Monitor Closely (1)letermovir increases levels of pravastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of letermovir with pravastatin may require a dosage reduction. Closely monitor patients for myopathy and rhabdomyolysis. When letermovir is coadministered with cyclosporine, the dose of pravastatin should not exceed 20 mg PO qDay.

  • lomitapide

    Monitor Closely (2)pravastatin increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.

    lomitapide increases levels of pravastatin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing dose when used concomitantly with lomitapide.

  • lonafarnib

    Monitor Closely (1)lonafarnib will increase the level or effect of pravastatin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Lonafarnib is a weak P-gp inhibitor. Monitor for adverse reactions if coadministered with P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicities. Reduce P-gp substrate dose if needed.Serious – Use Alternative (1)pravastatin will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.

  • mesterolone

    Monitor Closely (1)mesterolone increases toxicity of pravastatin by decreasing metabolism. Use Caution/Monitor. Risk of rhabdomyolysis (theoretical interaction based on case reports of combination of danazol and >20 mg/day lovastatin).

  • metyrapone

    Monitor Closely (1)metyrapone increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • midazolam intranasal

    Monitor Closely (1)pravastatin will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation.

  • mifepristone

    Monitor Closely (1)mifepristone increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • mipomersen

    Monitor Closely (1)mipomersen increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs; OATP1B1 inhibitors may increase risk of myopathy.

  • nelfinavir

    Monitor Closely (1)nelfinavir increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • niacin

    Serious – Use Alternative (1)niacin, pravastatin.
    Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of rhabdomyolysis (>1 g/day niacin).

  • ombitasvir/paritaprevir/ritonavir & dasabuvir

    Monitor Closely (2)ombitasvir/paritaprevir/ritonavir & dasabuvir will increase the level or effect of pravastatin by decreasing hepatic clearance. Modify Therapy/Monitor Closely. Maximum daily dose of pravastatin should be limited to 40 mg/day

    ombitasvir/paritaprevir/ritonavir & dasabuvir increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • orlistat

    Minor (1)orlistat increases effects of pravastatin by pharmacodynamic synergism. Minor/Significance Unknown.

  • paclitaxel

    Monitor Closely (1)paclitaxel increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • pazopanib

    Monitor Closely (1)pazopanib increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • pioglitazone

    Monitor Closely (1)pioglitazone increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • ponatinib

    Monitor Closely (2)ponatinib increases levels of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

    ponatinib increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • ranolazine

    Monitor Closely (1)ranolazine increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • red yeast rice

    Contraindicated (1)pravastatin, red yeast rice.
    Either increases toxicity of the other by pharmacodynamic synergism. Contraindicated. May increase creatine kinase levels and increase risk of myopathy or rhabdomyolysis; red yeast rice contains monocolin K (reportedly identical to lovastatin).

  • repaglinide

    Monitor Closely (1)repaglinide increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • rifampin

    Monitor Closely (1)rifampin increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • ritonavir

    Monitor Closely (1)ritonavir increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • rosiglitazone

    Monitor Closely (1)rosiglitazone increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • ruxolitinib

    Minor (1)pravastatin will increase the level or effect of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

  • sacubitril/valsartan

    Monitor Closely (2)sacubitril/valsartan increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

    pravastatin will increase the level or effect of sacubitril/valsartan by Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure

  • saquinavir

    Monitor Closely (1)saquinavir increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • sarecycline

    Monitor Closely (1)sarecycline will increase the level or effect of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor for toxicities of P-gp substrates that may require dosage reduction when coadministered with P-gp inhibitors.

  • sotorasib

    Serious – Use Alternative (1)sotorasib will decrease the level or effect of pravastatin by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If use is unavoidable, refer to the prescribing information of the P-gp substrate for dosage modifications.

  • stiripentol

    Monitor Closely (1)stiripentol will increase the level or effect of pravastatin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing the dose of P-glycoprotein (P-gp) substrates, if adverse reactions are experienced when administered concomitantly with stiripentol.

  • tacrolimus

    Monitor Closely (1)tacrolimus increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • telmisartan

    Monitor Closely (1)telmisartan increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • tepotinib

    Serious – Use Alternative (1)tepotinib will increase the level or effect of pravastatin by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If concomitant use unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling.

  • tinidazole

    Monitor Closely (1)pravastatin will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

  • trazodone

    Minor (1)trazodone increases levels of pravastatin by unspecified interaction mechanism. Minor/Significance Unknown.

  • tucatinib

    Monitor Closely (1)tucatinib will increase the level or effect of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities.

  • valsartan

    Monitor Closely (2)pravastatin will increase the level or effect of valsartan by Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure

    valsartan increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor.
    Comment: OATP1B1 inhibitors may increase risk of myopathy.

  • vemurafenib

    Monitor Closely (1)vemurafenib increases levels of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

  • voclosporin

    Minor (1)voclosporin will increase the level or effect of pravastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

    • Teva-Pravastatin – Uses, Side Effects, Interactions

    How does this medication work? What will it do for me?

    Pravastatin belongs to the family of medications known as HMG CoA reductase inhibitors (“statins”). It is used in addition to diet and exercise to lower high cholesterol levels. Pravastatin works by blocking an enzyme that is needed to make cholesterol in the liver. Therefore, less cholesterol is made and levels of cholesterol in the blood decrease. Lowering cholesterol levels in the blood has been shown to reduce the risks associated with heart disease, such as heart attack.

    Pravastatin can be used to reduce the risk of death, heart attacks, stroke, angioplasty, and hospitalization for people with heart disease and normal to moderately high cholesterol. It is also used to reduce the risk of heart attacks, angioplasty, and death for people with high cholesterol who do not already have heart disease.

    The medication usually takes about 4 weeks to have a significant effect on cholesterol levels in your blood. After this time, your doctor will likely send you for a lab test to check for changes in your cholesterol levels.

    This medication may be available under multiple brand names and/or in several different forms. Any specific brand name of this medication may not be available in all of the forms or approved for all of the conditions discussed here. As well, some forms of this medication may not be used for all of the conditions discussed here.

    Your doctor may have suggested this medication for conditions other than those listed in these drug information articles. If you have not discussed this with your doctor or are not sure why you are taking this medication, speak to your doctor. Do not stop taking this medication without consulting your doctor.

    Do not give this medication to anyone else, even if they have the same symptoms as you do. It can be harmful for people to take this medication if their doctor has not prescribed it.

    What form(s) does this medication come in?

    10 mg
    Each pink-to-peach, rounded, rectangular, biconvex, compressed tablet, engraved “N” on one side and “10” on the other side, contains 10 mg of pravastatin. Nonmedicinal ingredients: calcium phosphate dibasic anhydrous, croscarmellose sodium, crospovidone, ferric oxide red, lactose anhydrous, microcrystalline cellulose, povidone, and sodium stearyl fumarate.

    20 mg
    Each yellow, rounded, rectangular-shaped, biconvex, compressed tablet, engraved “N” on one side and “20” on the other side, contains 20 mg of pravastatin. Nonmedicinal ingredients: calcium phosphate dibasic anhydrous, croscarmellose sodium, crospovidone, ferric oxide yellow, lactose anhydrous, microcrystalline cellulose, povidone, and sodium stearyl fumarate.

    40 mg
    Each green, rounded, rectangular, biconvex, compressed tablet, engraved “N” on one side and “40” on the other side, contains 40 mg of pravastatin. Nonmedicinal ingredients: calcium phosphate dibasic anhydrous, D&C Yellow No. 10 Aluminum Lake 18%-24%, FD&C Blue No. 1 Aluminum Lake 11%-13%, croscarmellose sodium, crospovidone, lactose anhydrous, microcrystalline cellulose, povidone, and sodium stearyl fumarate.

    How should I use this medication?

    Before starting pravastatin, you should be on a cholesterol-lowering diet. If appropriate, a program of weight control and physical exercise should be implemented.

    The recommended starting dose of pravastatin is 20 mg daily, taken with or without food in a single dose at bedtime. Your doctor will do blood tests to tell how well this dose is working for you and may gradually increase the dose to get the desired response. The maximum recommended dose for adults is 80 mg taken once daily.

    Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.

    For best results in lowering your cholesterol, it is very important that you closely follow the diet suggested by your doctor. It is also very important that you take pravastatin exactly as prescribed by your doctor.

    If you miss a dose of this medication, take it as soon as you remember and continue with your regular schedule. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.

    Store this medication at room temperature, protect it from light and moisture, and keep it out of the reach of children.

    Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.

    Who should NOT take this medication?

    Do not take this medication if you:

    • are allergic to pravastatin or any ingredients of this medication
    • are breast-feeding
    • are pregnant or plan to become pregnant
    • have active liver disease or unexplained increases in liver function tests

    What side effects are possible with this medication?

    Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent.

    The side effects listed below are not experienced by everyone who takes this medication. If you are concerned about side effects, discuss the risks and benefits of this medication with your doctor.

    The following side effects have been reported by at least 1% of people taking this medication. Many of these side effects can be managed, and some may go away on their own over time.

    Contact your doctor if you experience these side effects and they are severe or bothersome. Your pharmacist may be able to advise you on managing side effects.

    • abdominal pain
    • constipation
    • cough
    • diarrhea
    • dizziness
    • headache
    • heartburn
    • nausea
    • nightmares
    • rash
    • sexual problems
    • trouble sleeping

    Although most of the side effects listed below don’t happen very often, they could lead to serious problems if you do not seek medical attention.

    Check with your doctor as soon as possible if any of the following side effects occur:

    • anxiety or nervousness
    • chest pain
    • confusion
    • cough or shortness of breath
    • memory loss or forgetfulness
    • signs of depression (e.g., poor concentration, changes in weight, changes in sleep, decreased interest in activities, thoughts of suicide)
    • symptoms of high blood sugar (e.g., frequent urination, increased thirst, excessive eating, unexplained weight loss, poor wound healing, infections, fruity breath odour)
    • symptoms of liver problems (e.g., yellow skin or eyes, abdominal pain, dark urine, clay-coloured stools, loss of appetite, nausea and vomiting, or itching)
    • symptoms of muscle damage (unexplained muscle pain, tenderness or weakness, or brown or discoloured urine – especially if you also have a fever or a general feeling of being unwell)
    • vision problems (i.e., blurred vision)

    Stop taking the medication and seek medical attention immediately if any of the following occur:

    • severe skin rash, including skin blistering and peeling (possibly with headache, fever, sore throat or mouth, coughing, or aching)
    • symptoms of a serious allergic reaction (such as swelling of the face or throat, hives, or difficulty breathing)

    Some people may experience side effects other than those listed. Check with your doctor if you notice any symptom that worries you while you are taking this medication.

    Are there any other precautions or warnings for this medication?

    Before you begin using a medication, be sure to inform your doctor of any medical conditions or allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use this medication.

    Alcohol: People who drink large quantities of alcohol should be closely monitored by their doctor while they are taking this medication. Alcohol can increase the risk of developing liver problems with this medication. Tell your doctor if you drink more than 3 alcoholic drinks per day.

    Diabetes: Pravastatin may cause an increase in blood sugar levels and glucose tolerance may change. People with diabetes may find it necessary to monitor their blood sugar more frequently while using this medication.

    If you have diabetes or are at risk for developing diabetes, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.

    Diet: Pravastatin is not intended for use alone to reduce high cholesterol levels. It is important that a cholesterol-reducing diet along with appropriate exercise be attempted before taking any medication and continued while taking medication.

    Grapefruit juice: Tell your pharmacist or doctor if you regularly drink grapefruit juice, because grapefruit juice may interact with pravastatin.

    Kidney problems: If you have decreased kidney function or a history of kidney disease, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.

    Liver function: Pravastatin may reduce liver function and can cause liver failure. Laboratory signs of harmful effects to the liver occur in about 0.5% of adults who take pravastatin for extended periods. When the medication is stopped, the laboratory tests usually slowly return to normal.

    Your doctor may want to test your liver function regularly with blood tests while you are taking this medication. This medication should not be used by people with active liver disease or by people whose liver function tests are higher than normal. If you have a history of liver disease, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.

    If you experience symptoms of liver problems such as fatigue, feeling unwell, loss of appetite, nausea, yellowing of the skin or whites of the eyes, dark urine, pale stools, abdominal pain or swelling, and itchy skin, contact your doctor immediately.

    Lung inflammation: Lung inflammation (interstitial lung disease), causing difficulty breathing has occurred rarely in some people taking this medication. This complication can be serious and sometimes fatal. If you experience new or worsening shortness of breath or cough (with or without fever) at any time while you are taking pravastatin, contact your doctor immediately.

    Muscle effects: In rare cases, serious muscle damage has been associated with the use of statin medications (i.e., cholesterol-lowering medications whose names end in “-statin,” such as atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin), especially at higher doses. Before taking this medication, tell your doctor or pharmacist if you:

    • are over the age of 65
    • are taking other medications, including prescription, non-prescription and natural health products, as drug interactions are possible
    • are taking other cholesterol-lowering medication such as fibrates (gemfibrozil, fenofibrate) or niacin
    • are physically frail
    • do excessive physical exercise
    • have diabetes
    • have a family history of muscular disorders
    • have kidney or liver problems
    • have uncontrolled thyroid problems
    • have undergone surgery or other tissue injury
    • have had any past problems with the muscles (pain, tenderness), after using a statin
    • regularly drink three or more alcoholic drinks daily

    Report any unexplained muscle pain, tenderness, weakness, cramps, or any brown or discoloured urine to your doctor immediately, particularly if you are also experiencing malaise (a general feeling of being unwell) or fever.

    Pregnancy: This medication should not be taken during pregnancy, as it may cause harm to the developing baby. If you become pregnant while taking this medication, stop taking it immediately and contact your doctor.

    This medication should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking this medication, stop taking it immediately and contact your doctor.

    Breast-feeding: This medication passes into breast milk. If you are a breast-feeding mother and are taking pravastatin, it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.

    Children: There is limited experience with the use of this medication by children. The safety and effectiveness of using this medication have not been established for children under 16 years old.

    Seniors: If you are over 65 years old, your doctor will likely monitor you closely for muscle-related side effects.

    What other drugs could interact with this medication?

    There may be an interaction between pravastatin and any of the following:

    • “azole” antifungal medications (e.g., ketoconazole, itraconazole)
    • carbamazepine
    • certain HIV protease inhibitors (e.g., darunavir, letermovir, nelfinavir, saquinavir)
    • cholestyramine
    • colchicine
    • colesevelam
    • colestipol
    • cyclosporine
    • daptomycin
    • efavirenz
    • eltrombopag
    • fibrates (e.g., bezafibrate, gemfibrozil, fenofibrate)
    • hepatitis C antiviral medications (e.g., asunaprevir, daclatasvir, glecavir, ledipasvir, pibrentasvir, sofosbuvir, voxilaprevir)
    • macrolide antibiotics (e.g., clarithromycin, erythromycin)
    • niacin (nicotinic acid)
    • niacinamide
    • paroxetine
    • phenytoin
    • raltegravir
    • repaglinide
    • rifabutin
    • rifampin
    • rupatadine
    • teriflunomide
    • tolvaptan
    • warfarin

    If you are taking any of these medications, speak with your doctor or pharmacist. Depending on your specific circumstances, your doctor may want you to:

    • stop taking one of the medications,
    • change one of the medications to another,
    • change how you are taking one or both of the medications, or
    • leave everything as is.

    An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.

    Medications other than those listed above may interact with this medication. Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications that you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them.

    All material copyright MediResource Inc. 1996 – 2021. Terms and conditions of use. The contents herein are for informational purposes only. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Source: www.medbroadcast.com/drug/getdrug/Teva-Pravastatin

    Pravastatin Sodium | Healthgrades | (tablet)

    Brand Name: Pravastatin Sodium

    Generic Name: PRAVASTATIN SODIUM

    Drug Type: HUMAN PRESCRIPTION DRUG

    Route: ORAL

    Dosage Form: TABLET

    Data Current As Of: 2018-10-05

    Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.

    prevention of cardiovascular disease

    In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets are indicated to:

    • reduce the risk of myocardial infarction (MI).
    • reduce the risk of undergoing myocardial revascularization procedures.
    • reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes.

    Pravastatin sodium tablets are indicated:

    Pravastatin sodium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V).

    For the concurrent therapy of either cyclosporine, fibrates, niacin (nicotinic acid), or erythromycin, the risk of myopathy increases [see Warnings and Precautions (5.1) and Clinical Pharmacology ( 12.3 )].

    The risk of myopathy/rhabdomyolysis is increased with concomitant administration of cyclosporine. Limit pravastatin to 20 mg once daily for concomitant use with cyclosporine [see Dosage and Administration (2.5), Warnings and Precautions (5.1), and Clinical Pharmacology ( 12.3 )].

    The risk of myopathy/rhabdomyolysis is increased with concomitant administration of clarithromycin. Limit pravastatin to 40 mg once daily for concomitant use with clarithromycin [see Dosage and Administration (2.6), Warnings and Precautions (5.1), and Clinical Pharmacology ( 12.3 )].

    patient counseling information

    Patients should be advised to report promptly unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever [see Warnings and Precautions (5.1)].

    Manufactured In Czech Republic By:

    TEVA Czech Industries, s.r.o.

    Opava-Komarov, Czech Republic

    Manufactured For:

    TEVA PHARMACEUTICALS USA

    Sellersville, PA 18960

    Rev. O 5/2011

    • PRAVACHOL (tablet)
    • Pravastatin (tablet)

    Pravastatin Sodium (Sandoz) | healthdirect

    What it is used for

    As an adjunct to diet for the treatment of hypercholesterolaemia. Prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. Patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol/L) serum cholesterol levels. Patients with unstable angina pectoris (see Clinical Trials). As an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see Clinical Trials).

    How to take it

    The way to take this medicine is: Oral.
    This medicine is taken by mouth.

    • Store below 25 degrees Celsius
    • Protect from Moisture
    • Protect from Light
    • Shelf lifetime is 3 Years.

    You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

    Always read the label. If symptoms persist see your healthcare professional.

    Visual appearance

    light brown, mottled, oval tablet, scored on both sides and debossed with “P 40” on one side

    Images are the copyright of the Pharmacy Guild of Australia

    Do I need a prescription?

    What is the medicines and poisons schedule?

    All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’.

    You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

    close tooltip Ok

    This medicine is available from a pharmacist and requires a prescription. It is
    Schedule 4 : Prescription Only Medicine.

    open tool tip to find out more